Skip to Content


Vorinostat Enhances Treatment for AML

Conquest - Spring 2012

National trial tests drug 
with frontline therapy

Adding a drug that activates genes to frontline combination therapy for acute myeloid leukemia resulted in an 85% remission rate after initial treatment. Study patients received the drug vorinostat combined with chemotherapy drug cytarabine and idarubicin, an anthracycline antibiotic commonly used as chemotherapy.

Guillermo Garcia-Manero, M.D.

Vorinostat, known commercially as Zolinza®, is a histone deacetylase inhibitor — an exciting new class of potential anticancer agents for treating solid and hematological (leukemias, lymphomas and myeloma) cancers.

“The overall response rates are encouraging, and most higher risk patients did very well,” says Guillermo Garcia-Manero, M.D., professor in 
MD Anderson’s Department of Leukemia and lead investigator on the study.

He will be the principal investigator on a national Phase III clinical trial with this combination, conducted through the National Cancer Institute’s Cooperative Oncology Groups.

Reported in December 2011 at the 53rd Annual Meeting of the American Society of Hematology.

Resources: Acute Myeloid Leukemia

Care to Comment?

Email the editor to comment on a story or offer suggestions on topics you'd like to see covered in future issues of Conquest and Annual Report.

Make a difference

Your gift to MD Anderson makes a difference in the lives of cancer patients by supporting innovative patient care, research, education and prevention programs. You can Donate Now or learn more at myGiving to MD Anderson.

© 2015 The University of Texas MD Anderson Cancer Center